Leptin is associated with increased risk of myocardial infarction

Journal of Internal Medicine

Volumn 246, Issue 4, 1999, Pages 409-418

  Soderberg S ^a,c   Ahren B ^b   Jansson, J H ^a   Johnson, O ^a   Hallmans, G ^a   Asplund, K ^a   Olsson, T ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Leptin; Myocardial infarction; Nested case referent study; Risk factor

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; INSULIN; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; LEPTIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SWEDEN;

EID: 0032862037     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00571.x     Document Type: Article

References (44)

1. 1 Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. 2 Haffner SM. Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl 1997; 15: S25-30.
3. 3 Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-86.
4. 4 Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-81.
5. 5 Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
6. 6 Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-78.
7. 7 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
8. 8 Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-9.
9. 9 Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62.
10. 10 Schwartz MW, Seeley RJ. Seminars in medicine of the Beth Israel Deaconess Medical Center. Neuroendocrine responses to starvation and weight loss. N Engl J Med 1997; 336: 1802-11.
11. 11 Leyva F, Godsland IF, Ghatei M et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998; 18: 928-33.
12. 12 Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82: 2771-6.
13. 13 de Courten M, Zimmet P, Hodge A et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997; 14: 200-208.
14. 14 Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997; 30: 619-23.
15. 15 WHO, MONICA Project. (Prepared by Tunstall Pedoe II, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A.) Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
16. 16 WHO, MONICA Project Principal Investigators prepared by Tunstall-Pedoe. The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105-14.
17. 17 Västerbotten Intervention Program Manual (in Swedish). Department of Community Medicine, Västerbotten County Council, Umeå, Sweden, 1996.
18. 18 Brännström I. Community participation and social patterning in cardiovascular disease intervention. University of Umeå, Sweden: Dissertation, 1993.
19. 19 Stegmayr B, Asplund K. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. Neuroepidemiol 1992; 11: 204-13.
20. 20 Weinehall L, Johnson O, Jansson JH et al. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med 1998; 243: 99-107.
21. 21 Bray GA. An approach to the classification and evaluation of obesity. In: Björntorp P, Brodoff BN, eds. Obesity. Philadelphia: J. B. Lippincott Co. 1992.
22. 22 Huhtasaari F, Asplund K, Stegmayr B, Lundberg V, Wester PO. Trends in cardiovascular risk factors in the Northern Sweden MONICA Study: who are the winners? Cardiovasc Risk Factors 1993; 3: 215-21.
23. 23 Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998; 16: 171-6.
24. 24 Haffner SM, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL, Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997; 21: 393-9.
25. 25 Söderberg S, Ahrén B, Stegmayr B et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. Stroke 1999; 30: 328-37.
26. 26 Söderberg S, Ahrén B, Eliasson M, Johnson O, Olsson T. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999; 245: 533-43.
27. 27 Rainwater DL, Comuzzie AG, VandeBerg JL, Mahaney MC, Blangero J. Serum leptin levels are independently correlated with two measures of HDL. Atheroscler 1997; 132: 237-43.
28. 28 Avogaro P, Bon GB, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979; 1: 901-3.
29. 29 Ball M, Mann JI. Apoproteins: predictors of coronary heart disease? Br Med J 1986; 293: 769-70.
30. 30 Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females. Int J Clin Lab Res 1992; 21: 247-55.
31. 31 Meade TW, Ruddock V, Stirling Y, Chakrabati R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
32. 32 Saad MF, Khan A, Sharma A et al. Physiological insulinemia acutely modulates plasma leptin. Diabetes 1998; 47: 544-9.
33. 33 Kolaczynski JW, Nyce MR, Considine RV et al. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996; 45: 699-701.
34. 34 Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994; 37: 953-5.
35. 35 Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997; 46: 2040-43.
36. 36 Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-14.
37. 37 Grassi G, Seravalle G, Colombo M et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-42.
38. 38 Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 1996; 2: 589-93.
39. 39 Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-8.
40. 40 Couillard C, Lamarche B, Mauriege P et al. Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998; 21: 782-6.
41. 41 Van Cauter E, Blackman JD, Roland D, Spire JP, Refetofl S, Polonsky KS. Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. J Clin Invest 1991; 88: 934-42.
42. 42 Sinha MK, Ohannesian JP, Heiman ML et al. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 1996; 97: 1344-7.
43. 43 Gumbiner B, Van Cauter E, Beltz WF et al. Abnormalities of insulin pulsatilily and glucose oscillations during meals in obese noninsulin-dependent diabetic patients: effects of weight reduction. J Clin Endocrinol Metab 1996; 81: 2061-8.
44. 44 Saad MF, Riad-Gabriel MG, Khan A et al. Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 1998; 83: 453-9.